Identification of diagnosis-related contraindications based on the medication plan alone (2022) Andrikyan W, Then M, Gassmann KG, Tuemena T, Dürr P, Fromm M, Maas R Conference contribution A LC-HRMS method for drug exposure measurement of 57 oral anticancer drugs in human plasma (2022) Kehl N, Dürr P, Schlichtig K, Maas R, Fromm M, Geßner A, Taudte V Conference contribution LPA-induced phosphorylation of Filamin A regulates association with Myocardin-related transcription factor A (MRTF-A) and cellular senescence (2022) Konopa A, Meier M, Mühlich S Conference contribution Prescription of QT interval prolonging drugs in Germany and discrepancies between their Summary of Product Characteristics and the international CredibleMeds((R)) database (2022) Then M, Andrikyan W, Maas R, Fromm M Conference contribution The transmembrane protein tetraspanin 5 controls the effects of loss of the tumor suppressor deleted in liver cancer 1 (DLC1) on hepatocellular carcinoma (HCC) growth (2021) Schreyer L, Mittermeier C, Martin DE, Singer S, Liebl B, Gudermann T, Aigner A, Mühlich S Conference contribution Assessment values in biological material for carcinogenic substances by the example of 1,4-dichlorobenzene (2020) Weistenhöfer W, Drexler H, Hartwig A, Schmitz-Spanke S Conference contribution Clinical utility of the simplified 15-gene S3-score for prediction of outcome in clear cell renal cell carcinoma (2019) Buettner F, Winter S, Rausch S, Hennenlotter J, Kruck S, Stenzl A, Scharpf M, et al. Conference contribution Pesticide concentrations in urine of preschool children: results of the 2nd human biomonitoring study in North Rhine-Westphalia Germany (2019) Chovolou Y, Sievering S, Engelmann J, Göen T, Schettgen T, Kraft M Conference contribution Identification of the negative gating modulator of the transient receptor potential cation channel TRPM7 NS8593 as a novel inhibitor of MRTF/SRF-dependent gene expression and hepatocarcinogenesis (2019) Voringer S, Zierler S, Chubanov V, Gudermann T, Mühlich S Conference contribution Medication safety in patients treated with new oral antitumor agents: a prospective, randomized investigation on the impact of intensified clinical pharmaceutical/ clinical pharmacological care on patient safety and well-being (AMBORA-Study - supported by the German Cancer Aid (70112447)) (2019) Duerr P, Schlichtig K, Dörje F, Fromm M Conference contribution